New Virus Identified in Blood Supply
By LabMedica International staff writers Posted on 30 Sep 2015 |
Image: The HiSeq 2500 sequencing platform (Photo courtesy of Illumina).
Transfusion of blood or blood-derived products can save lives and improve health but requires safety measures for preventing bystander transmission of infectious agents.
To investigate the transmission of novel infectious agents by blood transfusion, changes in the virome composition of blood transfusion recipients pre- and post-transfusion has been studied.
An international group of scientists led by those at Columbia University (New York, NY, USA) collected serum samples from four participating blood centers distributed across the USA from July 1974 through June 1980. They performed high-throughput sequencing on blood samples from 46 individuals in the in the Transfusion-Transmitted Viruses Study (TTVS). They also performed high-throughput sequencing on samples from 106 individuals in the Multicenter Hemophilia Cohort Study who received plasma-derived clotting factor concentrates.
Total ribonucleic acid (RNA) extracts were reverse transcribed using a SuperScript III kit (Invitrogen Life Technologies; Carlsbad, CA, USA) with random hexamer primers. After processing, samples with low concentrations were amplified by increasing polymerase chain reaction (PCR) cycle numbers from 9 to 14. All sequencing was done on the Illumina HiSeq 2500 platform (Illumina; San Diego, CA, USA), yielding an average of 150 million reads per sequencing lane.
The team analyzed samples both pre- and post-transfusion and along with a variety of known viruses, they identified a new virus in two individuals. The virus was only present in post-transfusion samples, and additional tests showed that both patients were able to clear the virus. Genetic analysis determined that the novel human virus, human hepegivirus 1 (HHpgV-1) was related to Hepatitis C virus (HCV) and human Pegivirus (HPgV; formerly called GB virus C or Hepatitis G virus). Genomic testing of 70 additional individuals in the TTVS study failed to detect further cases of the virus detected. HHpgV-1 was found in serum samples from two blood transfusion recipients and two hemophilia patients who had received plasma-derived clotting factor concentrates.
Amit Kapoor, PhD, an assistant professor and lead author of the study said, “HHpgV-1 is unique because it shares genetic similarity with both highly pathogenic HCV and the apparently non-pathogenic HPgV. People need to be aware of this new infection in humans. We just don't know how many viruses are transmitted through the blood supply. There are so many viruses out there, and they need to be characterized in order to ensure that transfusions are safe.” The study was published on September 22, 2015, in the journal mBio.
Related Links:
Columbia University
Invitrogen Life Technologies
Illumina
To investigate the transmission of novel infectious agents by blood transfusion, changes in the virome composition of blood transfusion recipients pre- and post-transfusion has been studied.
An international group of scientists led by those at Columbia University (New York, NY, USA) collected serum samples from four participating blood centers distributed across the USA from July 1974 through June 1980. They performed high-throughput sequencing on blood samples from 46 individuals in the in the Transfusion-Transmitted Viruses Study (TTVS). They also performed high-throughput sequencing on samples from 106 individuals in the Multicenter Hemophilia Cohort Study who received plasma-derived clotting factor concentrates.
Total ribonucleic acid (RNA) extracts were reverse transcribed using a SuperScript III kit (Invitrogen Life Technologies; Carlsbad, CA, USA) with random hexamer primers. After processing, samples with low concentrations were amplified by increasing polymerase chain reaction (PCR) cycle numbers from 9 to 14. All sequencing was done on the Illumina HiSeq 2500 platform (Illumina; San Diego, CA, USA), yielding an average of 150 million reads per sequencing lane.
The team analyzed samples both pre- and post-transfusion and along with a variety of known viruses, they identified a new virus in two individuals. The virus was only present in post-transfusion samples, and additional tests showed that both patients were able to clear the virus. Genetic analysis determined that the novel human virus, human hepegivirus 1 (HHpgV-1) was related to Hepatitis C virus (HCV) and human Pegivirus (HPgV; formerly called GB virus C or Hepatitis G virus). Genomic testing of 70 additional individuals in the TTVS study failed to detect further cases of the virus detected. HHpgV-1 was found in serum samples from two blood transfusion recipients and two hemophilia patients who had received plasma-derived clotting factor concentrates.
Amit Kapoor, PhD, an assistant professor and lead author of the study said, “HHpgV-1 is unique because it shares genetic similarity with both highly pathogenic HCV and the apparently non-pathogenic HPgV. People need to be aware of this new infection in humans. We just don't know how many viruses are transmitted through the blood supply. There are so many viruses out there, and they need to be characterized in order to ensure that transfusions are safe.” The study was published on September 22, 2015, in the journal mBio.
Related Links:
Columbia University
Invitrogen Life Technologies
Illumina
Latest Hematology News
- Next Generation Instrument Screens for Hemoglobin Disorders in Newborns
- First 4-in-1 Nucleic Acid Test for Arbovirus Screening to Reduce Risk of Transfusion-Transmitted Infections
- POC Finger-Prick Blood Test Determines Risk of Neutropenic Sepsis in Patients Undergoing Chemotherapy
- First Affordable and Rapid Test for Beta Thalassemia Demonstrates 99% Diagnostic Accuracy
- Handheld White Blood Cell Tracker to Enable Rapid Testing For Infections
- Smart Palm-size Optofluidic Hematology Analyzer Enables POCT of Patients’ Blood Cells
- Automated Hematology Platform Offers High Throughput Analytical Performance
- New Tool Analyzes Blood Platelets Faster, Easily and Accurately
- First Rapid-Result Hematology Analyzer Reports Measures of Infection and Severity at POC
- Bleeding Risk Diagnostic Test to Reduce Preventable Complications in Hospitals
- True POC Hematology Analyzer with Direct Capillary Sampling Enhances Ease-of-Use and Testing Throughput
- Point of Care CBC Analyzer with Direct Capillary Sampling Enhances Ease-of-Use and Testing Throughput
- Blood Test Could Predict Outcomes in Emergency Department and Hospital Admissions
- Novel Technology Diagnoses Immunothrombosis Using Breath Gas Analysis
- Advanced Hematology System Allows Labs to Process Up To 119 Complete Blood Count Results per Hour
- Unique AI-Based Approach Automates Clinical Analysis of Blood Data